Friday 19 April 2019 ,
Friday 19 April 2019 ,
Latest News
  • Awareness campaign about disaster urgently needed: PM
  • 5 to die in C’nawabganj for killing girl after rape
  • 7 MoUs likely to be signed during PM’s Brunei visit
  • 4 killed in Dinajpur, Feni road crashes
  • No one safe in the country: Fakhrul
  • 200 shops gutted in Malibagh kitchen market fire
21 January, 2019 00:00 00 AM

FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination

drugs.com
FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination

The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

"While strong vaccination programs are in place for young adolescents, a single Tdap immunization does not offer lifetime protection against pertussis due to waning immunity," said David P. Greenberg, M.D., Regional Medical Head North America at Sanofi Pasteur. "The licensure of Adacel as the first Tdap vaccine in the U.S. for repeat vaccination is an important step for eligible patients and offers flexibility for health care providers to help manage their immunization schedules."

The FDA licensure was based on clinical data from a study of the safety and effectiveness of repeat Adacel vaccination in adults. In the study of more than 1,300 adults (aged 18 through 64 years), participants received either Adacel vaccine or a tetanus-diphtheria (Td) vaccine 8-12 years after a previous dose of Adacel vaccine. The results of the study published in the Journal of the Pediatric Infectious Diseases Society showed a second dose of Adacel vaccine in adults administered 8-12 years after a previous dose found no significant differences in adverse events between vaccine groups.1 A total of 87.7% of Tdap vaccine recipients (n=999) and 88.0% of Td vaccine recipients (n=328) reported at least 1 injection-site reaction.

Sanofi Pasteur has provided the results of the study to the CDC's Advisory Committee on Immunization Practices for their consideration in future recommendations.

The U.S. Centers for Disease Control and Prevention (CDC) currently recommends a single dose of Tdap vaccine for adolescents and adults, and for pregnant women during every pregnancy. Tdap helps protect adolescents and adults and may prevent the spread of the infection to babies and young children who are still building immunity. Despite the CDC-recommendation, nearly three of four adults have not received the Tdap vaccine.

Indication for Adacel Vaccine

Adacel vaccine is given to people 10 through 64 years of age to help prevent tetanus (lockjaw), diphtheria, and pertussis (whooping cough).

Important Safety Information for Adacel Vaccine

Adacel vaccine should not be given to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine. Some signs of severe allergic reactions are hives, swelling of the throat, low blood pressure, shock, and difficulty breathing. If you begin to experience any of these signs seek treatment right away. These reactions are rare and usually occur before leaving the doctor's office.

For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex‐sensitive individuals. The vial stopper is not made with natural rubber latex.

Tell your doctor if you have ever experienced a severe brain disorder, such as encephalopathy (altered consciousness), Guillain‐Barré syndrome (severe muscle weakness), brachial neuritis (inflammation of nerves in the arms), or an Arthus‐type reaction (severe, exaggerated swelling involving an injection site) after a previous dose of a tetanus toxoid‐ or pertussis antigen‐containing vaccine.

Fainting can occur shortly after injecting vaccines, including Adacel.

If you notice any other problems or symptoms following vaccination, please contact your health care professional promptly.

After the first and second dose of Adacel, the most frequently reported side effects were pain, swelling, and redness at the injection site; headache, body ache or muscle weakness, tiredness, muscle aches, and general discomfort.

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Haemophilia, a bleeding disorder, is our cover story this week. Haemophilia is caused by a deficiency in one of the blood clotting factors. Haemophilia…
Haemophilia and World Haemophilia Day

Haemophilia and World Haemophilia Day

World Haemophilia Day is an international awareness day for haemophilia and other bleeding disorders. It is held annually on April 17, date of the birthday…
Haemophilia A: Genetic testing and what to expect

Haemophilia A: Genetic testing and what to expect

LANA BARHUM   Genetic testing for Hemophilia A is widely available and includes carrier testing, direct DNA mutation testing, linkage testing, and…
Blood disorders and its affects

Blood disorders and its affects

Blood disorders can affect any of the three main components of blood: Red blood cells, which carry oxygen to the body's tissues White blood cells,…
Bleeding tendencies in children

Bleeding tendencies in children

Rahim, a 3 year old boy hailing from Manikgonj presented in Paediatric OPD of Dhaka Shishu Hospital with his mother who complained that Rahim had fine…
10 facts on blood transfusion

10 facts on blood transfusion

Blood transfusion saves lives and improves health, but many patients requiring transfusion do not have timely access to safe blood. The need for blood…
Bruises and its treatments

Bruises and its treatments

A bruise is a common skin injury that results in a discoloration of the skin. Blood from damaged blood cells deep beneath the skin collects near the surface…
A tiny cry for help from inside the liver could lead to better treatment

A tiny cry for help from inside the liver could lead to better treatment

On a normal day, the cells of a human liver do what they do best—making key blood proteins, clearing toxins from the blood and sending their remains…
Food better than supplements for longevity

Food better than supplements for longevity

 TRISHA CALVO A new Tufts University study involving more than 27,000 Americans is the latest research to show that most supplements may not do much…
icddr,b and partners explore pathways of antibiotic use in Bangladesh and ways to intervene

icddr,b and partners explore pathways of antibiotic use in Bangladesh and ways to intervene

Recently, scientists at icddr,b in collaboration with Loughborough University, Durham University and the University of Bristol, UK have organised a dissemination…
Recurrence score may cut costs for high-risk breast cancer care

Recurrence score may cut costs for high-risk breast cancer care

Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients…
Call to ensure universal health coverage

Call to ensure universal health coverage

Health experts called for taking necessary steps for ensuring universal health coverage across the country in the greater interest of the country. A huge…
FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

ViiV Healthcare recently announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting